Regulatory perspectives on pharmacogenomics: A review of the literature on key issues faced by the United States Food and Drug Administration

Medical Care Research and Review

Volumn 63, Issue 3, 2006, Pages 301-326

  Phillips, Kathryn A ^a   Van Bebber, Stephanie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetics; Government industry relationships; Health technologies; Pharmacogenomics; Regulation

Indexed keywords

DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; GENETIC ANALYSIS; HUMAN GENOME PROJECT; MEDICAL TECHNOLOGY; PHARMACOGENOMICS; PRACTICE GUIDELINE; PUBLIC HEALTH; REVIEW; RISK BENEFIT ANALYSIS; SAFETY; UNITED STATES;

GOVERNMENT REGULATION; HUMANS; PHARMACOGENETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33646371252     PISSN: 10775587     EISSN: 15526801     Source Type: Journal    
DOI: 10.1177/1077558706287020     Document Type: Review

References (118)

1. Abbott, A. 2003. With your genes? Take one of these, three times a day. Nature 425:760-62.
2. Ahmad, S. R. 2003. Adverse drug event monitoring at the Food and Drug Administration: Your report can make a difference. Journal of General Internal Medicine 18:57-60.
3. Associated Reporters of Washington. 2003. Food and Drug Administration, Center for Evaluation and Research, Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting, April 23, 2003, at Rockville, Maryland.
4. Binzak, B. A. 2003. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process. Food and Drug Law Journal 58 (1): 103-27.
5. Blois, D. W. 2003. Response from Merck & Co., Inc to draft Guidance for Industry and FDA reviewers: Multiplex tests for heritable DNA markers, mutations, and expression patterns, June 27, 2003. http://www.fda.gov.
6. Branca, M. 2002. FDA fosters pharmacogenomics. Bio-IT World June 12, 2002. http:// www.bio-itworld.com/archive/061202/horizons_lesko.html (accessed January 7, 2004).
7. Brazell, C., A. Freeman, and M. Mosteller. 2002. Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance. British Journal of Clinical Pharmacology 53:224-31.
8. Brazma, A., P. Hingamp, J. Quackenbush, G. Sherlock, P. Spellman, C. Stoeckert, J. Aach, et al. 2001. Minimum information about microarray experiment (MIAME) - Towards standards for microarray data. Nature Genetics 29:365-71.
9. Bristol, L. A. 2002. A regulatory protocol for pharmacogenomics services. Pharmacogenomics Journal 2:83-86.
10. Buchanan, A., A. Califano, J. Kahn, E. McPherson, J. Robertson, and B. Brody. 2002. Pharmacogenetics: Ethical issues and policy options. Kennedy Institute of Ethics Journal 12 (1): 1-15.
11. Burnett, L., K. Barlow-Stewart, A. L. Proos, and H. Aizenberg. 2003. The "GeneTrustee": A universal identification system that ensures privacy and confidentiality for human genetic databases. Journal of Law and Medicine 10 (4): 506-13.
12. Carpenter, D. P. 2004. The political economy of FDA drug review: Processing, politics, and lessons for policy. Health Affairs (Millwood) 23 (1): 52-63.
13. Center for Medicaid & Medicare Services. 2003. CLIA Program: Clinical laboratory improvement amendments, http://cms.hhs.gov/clia/.
14. Collins, F. S, E. D. Green, A. E. Guttmacher, and M. S. Guyer. 2003. A vision for the future of genomics research. Nature 422:835-47.
15. Danzon, P., and A. Towse. 2002. The economics of gene therapy and of pharmacogenetics. Value Health 5 (1): 5-13.
16. Davis, A. F., and R. M. Long. 2002. Pharmacogenetics research network and knowledge base second scientific meeting. Pharmacogenomics Journal 2:293-96.
17. Drug Information Association. 2004. Co-development of drug, biological, and device products (meeting announcement). http://www.diahome.org (accessed July 14, 2004).
18. Drug Information Association, U.S. Food and Drug Administration, Pharmacogenetics Working Group, Pharmaceutical Research and Manufacturers of America, and Biotechnology Industry Organization. 2005. Pharmacogenomics in drug development and regulatory decision making - Workshop 3: Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines (workshop announcement and overview). http://www.diahome.org (accessed February 7, 2005).
19. Editorial. 2002. What's brewing in genetic testing? Nature Genetics 32 (4): 553-54.
20. _. 2003. Getting a grip on genetic testing? Nature Medicine 9 (2): 147.
21. Eisenberg, R. S. 2003. Will pharmacogenomics alter the role of patents in drug development? Pharmacogenomics 3 (5): 571-74.
22. Evans, W. E., and M. K. Relling. 2004. Moving towards individualized medicine with pharmacogenomics. Nature 429:464-68.
23. FDA Science Board. 2004. Science Board to the Food and Drug Administration. http://www.fda.gov/oc/advisory/sci.html (accessed March 30, 2004).
24. FDC Reports. 2004. FDA Pharmacogenomics Advisory Committee will oversee data submission. The Pink Sheet, March 22, 2004.
25. FDC Reports Inc. 2003. Drug development too risky without pharmacogenomics, McClellan says. Special reprint for Gennaissance Pharmaceuticals, Inc. In The Pink Sheet, November 17, 2003. http://www.genaissance.com/aboutus/news/p031117a. pdf (accessed December 3, 2003).
26. Feigal, D. W., and S. Gutman. 2003. Drug development, regulation, and genetically guided therapy. In Pharmacogenomics: Social, ethical, and clinical dimensions, edited by M. A. Rothstein. Hoboken, NJ: John Wiley.
27. Frank, R., and R. Hargreaves. 2003. Clinical biomarkers in drug discovery and development. Nature Reviews: Drug Discovery 2:566-80.
28. Freeman, K. 2004. Toxicogenomics data: The road to acceptance. Environmental Health Perspectives 112 (12): A678-85.
29. Fuhrmans, V. 2003. Roche test promises to tailor drugs to patients. Wall Street Journal, June 25, A3.
30. Geetter, J. S. 2002. Coding for change: The power of the human genome to transfer the American health insurance system. American Journal of Law & Medicine 28: 1-76.
31. Genentech, Inc. 2003. Drug prescribing information: Herceptin (Trastuzumab). http:// www.gene.com/gene/products/information/oncology/herceptin/insert.jsp (accessed November 7, 2003).
32. Gollust, S. E., S. C. Hull, and B. S. Wilfond. 2002. Limitations of direct-to-consumer advertising for clinical genetic testing. Journal of the American Medical Association 288 (14): 1762-67.
33. Gutman, S. 1999. The role of Food and Drug Administration regulation of in vitro diagnostic devices - Applications to genetics testing. Clinical Chemistry 45 (5): 746-49.
34. _. 2003. FDA's oversight of labeling, advertising and marketing of genetic tests. Paper presented at the meeting of the Secretary's Advisory Committee on Genetics Health and Society, October 22, Washington, DC.
35. _. OIVD requests a meeting with Roche Diagnostics regarding the AmpliChip CYP450 microarray. http://www.fda.gov (accessed July 28, 2003).
36. Hackett, J. L., and L. J. Lesko. 2003. Microarray data - The US FDA, industry and academia. Nature Biotechnology 21 (7): 742-43.
37. Hampton, T. 2004. FDA seeks genome-based drug data. Journal of the American Medical Association 291 (1): 32-33.
38. Holtzman, N. A. 1999. Are genetic tests adequately regulated? Science 286:409.
39. Huang, A. 1998. FDA regulation of genetic testing: Institutional reluctance and public guardianship. Food and Drug Law Journal 53 (3): 555-91.
40. Issa, A.M. 2002. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nature Reviews: Drug Discovery 1:300-308.
41. _. 2003. Pharmacogenomic profiling in postmarketing surveillance: Prospects and challenges. Pharmacogenomics 4 (5): 647-55.
42. _. 2004. The regulation of pharmacogenomics-based drugs and policy making. Current Topics in Medicinal Chemistry 4 (13): 1455-60.
43. Juengst, E. T. 2003. Ethical, legal, and social implications of genetic technologies. Paper presented at the inaugural meeting of the Secretary's Advisory Committee on Genetics Health and Society, June 11-12, Washington, DC.
44. Lesko, L. J. 2003a. Follow up to meeting on GDS Conference, November 24, 2003.
45. _. 2003b. Impact of pharmacogenomics on FDA's drug review process. Paper presented at the meeting of the Secretary's Advisory Committee on Genetics Health and Society, October 22, Washington, DC.
46. _. 2003c. Pharmacogenetics: Improvement of existing drug treatments. Paper presented to the Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee meeting, April 23, Rockvill, MD.
47. Lesko, L. J., and R. A. Salerno. 2002. 2002 Workshop on pharmacogenetics/ pharmacogenomics in drug development and regulalatory decision-making. Sponsored by the FDA and companies represented on the Pharmaceutical Research Manufacturers of America (PhRMA) Preclinical Safety Committee (DruSafe), and the Pharmacogenetics Working Group (PWG). http://www.fda.gov.
48. Lesko, L. J., R. A. Salerno, B. B. Spear, D. C. Anderson, T. Anderson, C. Brazell, J. Collins, et al. 2003. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: Report of the first FDA-PWG-PhRMA-DruSafe Workshop. Journal of Clinical Pharmacology 43:342-58.
49. Lesko, L. J., and J. Woodcock. 2002. Pharmacogenomic-guided drug development: Regulatory perspective. Pharmacogenomics Journal 2 (1): 20-24.
50. _. 2004. Translation of pharmacogenomics and pharmacogenetics: A regulatory perspective. Nature Reviews: Drug Discovery 3:763-69.
51. Lewis, C. 2003. The impact of direct-to-consumer advertising. FDA Consumer Magazine, March-April.
52. Lindpaintner, K. 2003. Pharmacogenetics and the future of medical practice. Journal of Molecular Medicine 81 (3): 141-53.
53. Manasco, P. K., and T. E. Arledge. 2003. Drug development strategies. In Pharmacogenomics: Social, ethical, and clinical dimensions, edited by M. A. Rothstein. Hoboken, NJ: John Wiley.
54. Mannix, D. 2003. Response from Amersham to draft Guidance for Industry and FDA reviewers: Multiplex tests for heritable DNA markers, mutations, and expression patterns, July 17, 2003. http://www.fda.gov.
55. Mansfield, E., and M. M. Schoonmaker. 2003. New draft guidance for multiplex tests. http://www.fda.gov/cdrh/oivd/presentations/mansfield-042403.html.
56. Marshall, E. 2003. Preventing toxicity with a gene test. Science 302:588-90.
57. McClellan, M. B. 2003. Technology and innovation: Their effects on cost growth of healthcare. Before the Joint Economic Committee United States Congress, July 9. http://www.fda.gov.
58. Melzer, D., D. Detmer, and R. Zimmern. 2003. Pharmacogenetics and public policy: Expert views in Europe and North America. Pharmacogenomics 4 (6): 1-3.
59. Melzer, D., A. Raven, D. E. Detmer, T. Ling, and R. L. Zimmern. 2003. My very own medicine: What must I know? Cambridge, UK: University of Cambridge.
60. Melzer, D., R. L. Zimmern, and T. Ling. 2003. Regulatory options for pharmacogenetics. Pharmacogenomics 4 (5): 527-30.
61. Miercke, B. V. S., C. Bush-Donovan, and J. A. Kolberg. 2003. Response from Bayer HealthCare Diagnostics Division to draft Guidance for Industry and FDA reviewers: Multiplex tests for heritable DNA markers, mutations, and expression patterns, July 16. http://www.fda.gov.
62. National Committee for Clinical Laboratory Standards. 2004. Determining clinical utility of genetic tests. Noted on NCCLS Web site. http://www.nccls.org/Content/ NavigationMenu/Standards_Development/NCCLS_Standards_Development/ Committees_and_Projects/Area_Committee_on_Molecular_Methods/Projects_ in_Development8/Projects_in_Development.htm.
63. Nuffield Council on Bioethics. 2003. Pharmacogenetics: Ethical issues. http://www. nuffieldbioethics.org (accessed October 25, 2003).
64. Oestreicher, P. 2001. 4th annual pharmacogenomics and medicine lectures. Pharmcogenomics 2 (3): 291-96.
65. Pearson, H. 2002. At-home DNA tests are here. Wall Street Journal, June 25, D6.
66. Petricoin, E. G., J. L. Hackett, L. J. Lesko, R. K. Puri, S. I. Gutman, K. Chumakov, J. Woodcock, D. W. Feigal, K. C. Zoon, and F. D. Sistare. 2003. Medical applications of microarray technologies: A regulatory perspective. Nature Genetics 32 (Suppl.): 474-79.
67. Pharmacogenetics Working Group. 2001. Terminology for sample collection in clinical genetic studies. Pharmacogenomics Journal 1:101-3.
68. Phillips, K. A., S. J. Flatt, K. R. Morrison, and T. J. Coates. 1995. Potential use of home HIV testing. New England Journal of Medicine 332 (19): 1308-10.
69. Phillips, K. A., and S. L. Van Bebber. 2004. Cost-effectiveness of pharmacogenomic interventions: A systematic review of the literature. Pharmacogenomics 5 (8): 1139-49.
70. _. 2005. Where could genetic testing to individualize drug therapies have the greatest impact? The example of genetic testing for CYP2D6 variant alleles. Nature Reviews: Drug Discovery 4 (6): 500-509.
71. Phillips, K. A., S. L. Van Bebber, B. Alldrege, A. M Issa, J. S. Haas, D. Bates, and H. A. Huskamp. 2005. Can pharmacogenomics improve drug safety? Implications for research and policy. Abstract presented at the Academy health annual meeting, June 26-28, Boston.
72. Phillips, K. A., S. L. Van Bebber, D. Veenstra, and J. Sakowski. 2003. The economics of pharmacogenomics. Current Pharmacogenomics 1 (4): 277-84.
73. Phillips, K. A., D. Veenstra, S. L. Van Bebber, and J. Sakowski. 2003. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 4 (3): 231-39.
74. Phillips, K. A., D. L. Veenstra, E. Oren, J. K. Lee, and W. Sadee. 2001. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. Journal of the Academy of Marketing Science 286 (18): 2270-79.
75. Phillips, K. A., D. L. Veenstra, S. D. Ramsey, S. L. Van Bebber, and J. Sakowski. 2004. Genetic testing and pharmacogenomics: Issues for determining the impact to health care delivery and costs. American Journal of Managed Care 10 (7): 425-32.
76. Phillips, K. A., D. L. Veenstra, and W. Sadee. 2000. Implications of the genetics revolution for health services research: Pharmacogenomics and improvements in drug therapy. Health Services Research 35 (5): 1-12.
77. Pietrusko, R. G. 2003. Response from Millenium Pharmaceuticals to draft Guidance for Industry and FDA reviewers: Multiplex tests for heritable DNA markers, mutations, and expression patterns. June 20. http://www.fda.gov.
78. Raczkowski, V. F. C. 2000. Update on FDA's pediatric labeling regulations and initiatives on patient drug information. Paper presented at the annual meeting of the Drug Information Association, June 14. http://www.fda.gov/cder/present/dia-62000/ vicrac2/index.htm (accessed January 22, 2004).
79. Ratner, M. L. 2003. Pharmacogenomic data and labeling: A less-safe harbor for existing drugs? Windhover's update. http://www.windhover.com/update/05252003/ 2003800094.htm (accessed January 26, 2004).
80. Robertson, J. A. 2001. Consent and privacy in pharmacogenetic testing. Nature Genetics 28 (3): 207-9.
81. Robertson, J. A., B. Brody, A. Buchanan, J. Kahn, and E. McPherson. 2002. Pharmacogenetic challenges for the health care system. Health Affairs 21 (4): 155-67.
82. Rosenthal, M. B., E. R. Berndt, J. M. Donohue, R. G. Frank, and A. M. Epstein. 2002. Promotion of prescription drugs to consumers. New England Journal of Medicine 346 (7): 498-505.
83. Roses, A. D. 2000. Pharmacogenetics and the practice of medicine. Nature 405:857-65.
84. _. 2004. Pharmacogenetics and drug development: The path to safer and more effective drugs. Nature Reviews: Genetics 5 (9): 645-56.
85. Rouse, R., and G. Hardiman. 2003. Microarray technology - An intellectual property retrospective. Pharmacogenomics 4 (5): 623-32.
86. Salerno, R. A., and L. J. Lesko. 2004. Pharmacogenomics in drug development and regulatory decision-making: The Genomic Data Submission (GDS) Proposal. Pharmacogenomics 5 (1): 25-30.
87. Savage, D. R. 2003. FDA guidance on pharmacogenomics data submission. Nature Reviews Drug Discovery 2:937-38.
88. Secretary's Advisory Committee on Genetic Testing. 2000a. Enhancing the oversight of genetic tests: Recommendations of the SACGT. Bethesda: Secretary's Advisory Committee on Genetic Testing, National Institute of Health.
89. _. 2000b. A public consultation on oversight of genetic tests, http://www4.od. nih.gov/oba/sacgt.htm.
90. Secretary's Advisory Committee on Genetics Health and Society. 2003a. Questions and answers with Wylie Burke and Nicholas Dracopoli. Paper presented at the inaugural SACGHS meeting, June 11-12, Washington, DC.
91. _. 2003b. Transcripts from the second meeting of the Secretary's Advisory Committee on Genetics Health and Society, October 22-23, Washington, DC. http:// www4.od.nih.gov/oba/SACGHS/meetings/October2003/SACGHS_Oct_2003. HTM (accessed February 14, 2006).
92. Shah, J. 2003. Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare. Nature Biotechnology 21 (7): 747-53.
93. Shalala, D. E., J. E. Henney, and J. Woodcock. 1999. From test tube to patient: Improving health through human drugs, http://www.fda.gov/cder.
94. Shi, L., W. Tong, F. Goodsaid, F. Freuh, H. Fang, T. Han, J. C. Fuscoe, and D. A. Casciano. 2004. QA/QC: Challenges and pitfalls facing the microarray community and regulatory agencies. Expert Review of Molecular Diagnosis 4 (6): 761-77.
95. Sistare, F. D. 2003. Applications of genomic technologies to improve recognition, understanding, and assessment of pharmaceutical actions: A focus on integrating gene expression data sets into regulatory practice. Paper presented to the Science Board Advisory Committee, April 9, 2003, Rockville, MD. http://www.fda.gov/ohrms/ dockets/ac/03/slides/3944s1.htm (accessed February 14, 2006).
96. Spear, B. B. 1999. Viewpoint - Pharmacogenomics: Today, tomorrow, and beyond. Drug Benefit Trends 11 (2): 53-54.
97. _. 2003. Pharmacogenomics in drug development. Paper presented to the FDA Science Board, April 9, 2003, Rockville, MD. http://www.fda.gov/ohrms/dockets/ ac/03/slides/3944s1_08-Spear.ppt (accessed February 14, 2006).
98. Strauss, A. L. 1990. Basics of qualitative research: Grounded theory procedures and techniques. Newbury Park, CA: Sage.
99. Sulston, J. 2003. Beyond release: The equitable use of genetic information. The Lancet 362:400-401.
100. Till, A. E. 2003. Response from Pharmaceutical Research and Manufacturers of America to draft Guidance for Industry and FDA reviewers: Multiplex tests for heritable DNA markers, mutations, and expression patterns, http://www.fda.gov.
101. Tsongalis, G. J. 2003. A reality check for molecular diagnostics in clinical practice. Pharmacogenomics 4 (5): 667-68.
102. Tunis, S. R., and H. Gelband. 1995. Health care technology in the United States. In Health care technology and its assessment in eight countries, edited by U.S. Congress and Office of Health Technology Assessment. Washington, DC: Government Printing Office.
103. U.S. Department of Health and Human Services, and U.S. Food and Drug Administration. 2003. Office of Combination Products annual report to Congress. http:// www.fda.gov/oc/combination/Congressreport.pdf.
104. _. 2004. Innovation or stagnation: Challenge and opportunity on the critical path to new medical products. www.fda.gov/oc/initiatives/criticalpath/white paper.html (accessed December 20, 2004).
105. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Office of In Vitro Diagnostic Device Evaluation and Safety, and Division of Immunology and Heamatology Devices. 2003. Multiplex tests for heritable DNA markers, mutations and expression patterns; draft Guidance for Industry and FDA reviewers. Available: www.fda.gov.
106. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and Center for Devices and Radiological Health (CDER). 2005. Guidance for Industry: Pharmacogenomic data submissions. http://www. fda.gov/cder/guidance/6400fnl.pdf (accessed April 26, 2005).
107. U.S. Food and Drug Administration. 2002. Improving innovation in medical technology: Beyond 2002. http://www.fda.gov 2002 (accessed June 17, 2003).
108. _. 2003. Pharmacogenomics in drug development and regulatory decision making - The Genomic Data Submission (GDS) Proposal, November 13-14, Washington, DC.
109. _. 2004. FDA clears first of kind genetic lab test. FDA News. http://www.fda. gov/bbs/topics/news/2004/new01149.html (accessed December 23, 2004).
110. Valdes, R. M. W. Linder, and S. A. Jortani. 2003. What is next in pharmacogenomics? Translating it to clinical practice. Pharmacoeconomics 4 (4): 499-505.
111. Varmus, H. 2002. Getting ready for gene-based medicine. New England Journal of Medicine 347 (19): 1526-27.
112. Veenstra, D. L., M. K. Higashi, and K. A. Phillips. 2000. Assessing the cost-effectiveness of pharmacogenomics. Pharmaceutical-Sciences, September 14, 2 (3, article 29). http:// www.aapspharmsci.org/view.asp?art=ps020329.
113. Weshler, J. 2003. From Genome Exploration to Drug Development. Pharmaceutical Technology June 2003:26-34.
114. Willey, J.C. 2003. Response from Gene Express Inc. to Draft Guidance for Industry and FDA Reviewers: Multiplex Tests for Heritable DNA Markers, Mutations, and Expression Patterns, July 23, 2003. www.fda.gov.
115. Winstead, E. R. 2003. Genomes and medicine - Part 1, New drugs new challenges: FDA tests genome data. Genome News Network. http://www.genomenewsnetwork. org/articles/09_03/fda_microarray.shtml (accessed September 29, 2003).
116. Woodcock, J. 2003a. Direct to consumer advertising of prescription drugs: Exploring the consequences. Statement before the Senate Special Committee on Aging, July 22. http://www.fda.gov/ola/2003/AdvertisingofPrescriptionDrugs0722.html (accessed February 9,2004).
117. _. 2003b. Draft Guidance for Industry: Pharmacogenomic data submissions. Paper presented at Genomic Data Submission conference, November 13, Washington, DC.
118. Zitner, A. 2002. Firms sell gene tests directly to public. Los Angeles Times, August 11, 2002, A1.